Long-Acting Injectable Buprenorphine

How it works

Benefits

Risks & contraindications

Evidence quality

Highlighted claims

• LAIB provides sustained buprenorphine release through a subcutaneous depot injection over an extended period. — Qualitative evidence of service user experiences and perspectives on long-acting injectable buprenorphine for opioid treatment: protocol for a scoping review
• LAIB eliminates the need for daily or frequent medication dispensing. — Qualitative evidence of service user experiences and perspectives on long-acting injectable buprenorphine for opioid treatment: protocol for a scoping review
• The long-term effectiveness of LAIB relative to oral formulations remains unclear. — Qualitative evidence of service user experiences and perspectives on long-acting injectable buprenorphine for opioid treatment: protocol for a scoping review
• Service users report LAIB can increase freedom, autonomy, travel flexibility, normality, and reduce stigma. — Qualitative evidence of service user experiences and perspectives on long-acting injectable buprenorphine for opioid treatment: protocol for a scoping review
• Some service users feel disconnected, less engaged, or ambivalent toward LAIB despite its benefits. — Qualitative evidence of service user experiences and perspectives on long-acting injectable buprenorphine for opioid treatment: protocol for a scoping review
• LAIB may improve treatment retention by maintaining controlled steady-state buprenorphine levels and reducing visit burden. — Qualitative evidence of service user experiences and perspectives on long-acting injectable buprenorphine for opioid treatment: protocol for a scoping review
• Some studies associate LAIB with improved quality of life, increased employment opportunities, and higher treatment satisfaction. — Qualitative evidence of service user experiences and perspectives on long-acting injectable buprenorphine for opioid treatment: protocol for a scoping review